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INTRODUCTION 
A zoonotic virus with periodic outbreaks occurring 
predominantly in the south-east Asian region, the 
Nipah virus (NiV) can also be transmitted through 
contaminated food or directly between humans. 
Persons infected with this illness, are seen with a 
range of symptoms and disease which include 
asymptomatic (subclinical) infection to acute 
respiratory illness and encephalitis which is fatal in 
nature.1 
 
A paramyxovirus related to Hendra virus, the first 
documented case of Nipah Virus emerged in Malaysia 
in 1998, and the outbreak also affected Singapore. 
The virus has been reported to reappear on many 
different occasions and causes severe infections that 
is associated with high mortality rates among the 
affected people.2 The only method to address this 
highly fatal and contagious disease is to provide 
symptomatic treatment to the affected people 
promptly.3  
 
The incidence of Nipah virus was observed in 
Bangladesh in the year 2001, and since then, nearly 
annual outbreaks been occurring in the country. 
Periodical occourence of this disease has been 
identified in two Indian states till now: West Bengal 
(2001, 2007) and Kerala (2018, 2019). 
 
In its first occurrence in West Bengal in the year 2001, 
a total of 66 cases and 45 mortalities  due to Nipah 
virus   were   reported. In the southern state of Kerela,  
 
 
 
in the year 2018, 17 deaths were seen from a total of 
the 19 reported cases from Kozhikode and 
Malappuram.4 
 
Owing to the high fatality rates of the viral infection, 
this review was written with the aim to provide the 
scientific community with a brief knowledge 
regarding the Nipah virus and its characteristics.  
 
THE NIPAH VIRUS 
The NiV is placed along with HeV in the genus 
Henipavirus of family Paramyxoviridae as it showed 
68% to 92% and 40% to 67% homology with HeV in 
protein‐coded regions and non‐translated regions. 
Variations in the strain has been observed between 
human NiV isolates collected from the outbreaks in 
Malaysia, India, and Bangladesh.5 
 
Although the virus predominantly spreads from  
animals to humans, one of the clearest illustrations of 
person-to-person transmission of NiV occurred 
during the Faridpur outbreak (2004), in which, the 
chain of infections transmission eventually involved 5 
generations and affected a total of  34 people. 6 
 
ETIOLOGY 
The natural reservoir for Nipah virus and related 
members of the genus Henipavirus are fruit bats of 
the genus Pteropus.7 However, both Hendra and 
Nipah viruses possess an exceptionally broad species 
tropism and both natural and experimental infections  
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of these two viruses have demonstrated their capacity 
to cause disease as is often fatal in horses, pigs, cats, 
dogs, ferrets, hamsters, guinea pigs, monkeys, and 
humans etc. Nipah virus and Hendra virus cause a 
systemic infection that is characterized as a wide-
spread vasculitis and endothelial cell tropism.8 
 
CLINICAL SIGNS AND SYMPTOMS 
Clinical symptoms of NiV infection are broad, 
ranging from the asymptomatic to very severe.7 The 
incubation period (in human beings) ranged from a 
period of 4 days to 2 months, with more than 90% of 
the infection seen at 2 weeks or lesser duration of 
time.8  
 
Affected patients presented with symptoms like fever, 
headache, dizziness, and vomiting, which developed 
into a clinical picture of severe encephalitis. Reduced 
level of consciousness and prominent signs of 
brainstem dysfunction, including abnormal doll's eye 
reflex, pupillary reflexes, vasomotor changes, 
seizures, and myoclonic jerks were seen in many 
patients.9 The neurological involvement was diverse 
and multifocal, including aseptic meningitis, diffuse 
encephalitis, and focal brainstem involvement. 
Cerebellar signs were relatively common. 
 
Certain neurological signs such as behavioural 
changes, spasms, uncoordinated gait and myoclonus 
were reported in patients from Bangladesh while 
cough was the com0monly presented respiratory 
symptom. Atypical pneumonia was reported in 14% 
cases in outbreak of this disease in Malaysia.10 
 
DIAGNOSIS 
Diagnosis of NiV is based on laboratory diagnostic 
tests which consists of detecting anti-NiV 
immunoglobulin M (IgM) and IgG antibody in the 
serum and cerebrospinal fluid (CSF). 
 
The most commonly used diagnostic method is the 
ELISA test, using monoclonal antibody-based 
antigen, for virus detection and for differentiating 
NiV from Hendra virus.11 Other methods available 
include the  serum neutralizing tests, RT-PCR for 
detection of viral RNA from serum, urine, and CSF, 
virus isolation and nucleic acid amplification test.12 
Magnetic resonance imaging (MRI) of the brain 
serves as a sensitive diagnostic tool in acute and 
relapse/late-onset NiV encephalitis, when the 
diagnostic sensitivity of ELISA is not reliable.12 
 
PREVENTIVE STRATEGIES13 
The various preventive strategies can be incorporated 
to prevent NiV transmission are as follows: 
1. Transmission of virus from patient to his/her 
attendant can be significantly reduced through 
frequent hand washing, avoiding sharing of food 
and/or bed with the affected person. 
2. Using gloves and masks while handling of infected 
body of the deceased person is an absolute measure 
that needs to be undertaken to avoid corpse to 
human transmission. In circumstances where the 
availibity of gloves and masks is limited,  thorough 
hand washing with soap and water immediately is 
advised to prevent disease transmission.  
3. Nosocomial transmission can be minimized by 
ensuring proper hand washing facilities, through the 
use of personal protective equipment (PPE) and 
isolation of the meningoencephalitis patients during 
NiV outbreaks. 
4. Proper care while washing and/or peeling of fruits 
followed by adoption of proper hand hygiene 
practices during meals.  
5. Use of various communication strategies like local 
television or radio channels and print media to be 
used to create awareness among people regarding the 
spread of this deadly virus.  
6. Implementing the Bamboo skirt method (to 
prevent contaminating the date palm sap) and sap 
branch method ( the shaved part of the tree is 
covered with its own branches, cloth or mosquito 
net) should be adopted to prevent infestation of fruits 
and other tree products from getting infected.14 
 
TREATMENT 
The treatment for NiV is supportive care only as no 
antiviral specifically available to treat this disease has 
been made available till date.  The antivirals ribavirin 
(Malaysian outbreak) and acyclovir (Singapore 
outbreak) have been used and they have significantly 
reduced the mortality rates of this deadly disease.  
 
CONCLUSION 
Keeping in mind the high fatality in the case of NiV 
infection, doctors and health professionals are 
advised to keep themselves updated regarding this 
disease, use personal protective equipment (PPEs) 
adequately to prevent the chances of transmission in 
them and initiate immediate  treatment for the ones 
suffering from this deadly disease, to lower the 
mortality risk among patients.  
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